Molecular pathogenesis and emerging targets of gastric adenocarcinoma

Ivey, Abby D.; Pratt, Hillary G; Boone, Brian A.

doi:10.1002/jso.26874

Cited by 6 publications

(2 citation statements)

References 178 publications

(331 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric adenocarcinoma is considered the 5th most common cancer type and ranked 3rd among high deaths causing cancers worldwide (Hudler, 2012;Moehler et al, 2022). It is most common in Asian populations, and prognosis and effectiveness of treatments depends on regional differences in disease progression and etiology (Ivey et al, 2022). The molecular and epidemiologic background of gastric cancers is unique.…”

Section: Introductionmentioning

confidence: 99%

“…Chemotherapy is typically recommended to reduce symptoms, control disease and prolong survival in patients with surgically unresectable gastric cancers. On the other hand, patients with tolerance to high toxicity are treated with fluoropyrimidine and platinum double with an additional chemotherapy (Cassetta and Pollard, 2018;Ivey et al, 2022). Despite the availability of these treatment options, the selection and efficacy of the treatment is challenging due to intra-tumoral heterogeneity mediated treatment resistance (Ivey et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery

Lin

Zeng

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Adenocarcinomas are one of the most common histological types of gastric cancer. It has been ranked fifth among common cancers and is the third among death causing cancers worldwide. The high mortality rate among patients with gastric cancer is because of its silent evolution, genetic heterogeneity, high resistance to chemotherapy as well as unavailability of highly effective therapeutic strategy. Until now a number of several treatment strategies have been developed and are being practiced such as surgery, chemotherapy, radio therapy, and immunotherapy, however, further developments are required to improve the treatment responses and reduce the side effects. Therefore, novel personal therapeutic strategies based on immunological responses should be developed by targeting different check points and key immune players. Targeting macrophages and related molecular elements can be useful to achieve these goals. In this minireview, we discuss the available treatment options, molecular underpinnings and immunological regulations associated with gastric adenocarcinoma. We further describe the possible check points and immunological targets that can be used to develop novel therapeutic options.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery

Lin

Zeng

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

show abstract

Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications

Zhang

Liu

et al. 2023

Pathology - Research and Practice

View full text Add to dashboard Cite

A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer

Ma¹,

Cui²,

Wang³

et al. 2022

Transl Cancer Res

View full text Add to dashboard Cite

Background: Accurate evaluation of human epidermal growth factor receptor 2 (HER2) status is very important for appropriate management of advanced gastric cancer (AGC) patients. In this study, we aimed to develop and validate a computed tomography (CT)-based radiomics signature for preoperative prediction of HER2 overexpression and treatment efficacy of trastuzumab in AGC. Methods:We retrospectively enrolled 536 consecutive AGC patients (median age, 59 years; interquartile range, 52-65 years; 377 male, 159 female) and separated them into a training set (n=357) and a testing set (n=179). Radiomic features were extracted from 3 different phase images of contrast-enhanced CT scans, and a radiomics signature was built based on highly reproducible features using the least absolute shrinkage and selection operator (LASSO) method. The predictive performance of the radiomics signature was assessed in the training and testing sets. Univariable and multivariable logistical regression analyses were used to identify independent risk factors of HER2 overexpression. Univariable and multivariable Cox regression analyses were used to identify the risk factors of overall survival (OS) and progression-free survival (PFS).The predictive value of the radiomics signature for treatment efficacy of trastuzumab was also evaluated. Results:The radiomics signature comprised eight robust features that demonstrated good discrimination ability for HER2 overexpression in the training set [area under the curve (AUC) =0.85] and the testing set (AUC =0.81). Multivariable Cox regression analysis revealed that the radiomics signature was an independent risk factor for OS [hazard ratio (HR) =2.01, P=0.001] and PFS (HR =1.32, P=0.01). The radiomics score of patients who achieved disease control was significantly lower than that of patients with progressive disease (P=0.023). Conclusions:The proposed radiomics signature showed favorable accuracy for prediction of HER2 overexpression and prognosis in AGC. It has promising potential as a noninvasive approach for selecting patients for target therapy.

show abstract

Molecular pathogenesis and emerging targets of gastric adenocarcinoma

Cited by 6 publications

References 178 publications

Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery

Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery

Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications

A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer

Contact Info

Product

Resources

About